News - Qureator, Inc.

News & Publications

Qureator’s Historic FDA IND Approval Based on Human-Relevant Data Highlighted in The BIO

November 25, 2025

Tags : Press highlights ,

Qureator and Physicians Committee for Responsible Medicine Announce Joint Workshop at SOT 2026

November 25, 2025

Tags : Activities ,

Paul Park Joins Qureator as Chief Business Officer

December 2, 2025

Tags : Spotlight ,

All
Activities
Press highlights
Spotlight

Select Category

AllActivitiesPress highlightsSpotlight

Paul Park Joins Qureator as Chief Business Officer

December 2, 2025

Tags : Spotlight ,

Qureator and Physicians Committee for Responsible Medicine Announce Joint Workshop at SOT 2026

November 25, 2025

Tags : Activities ,

Qureator’s Historic FDA IND Approval Based on Human-Relevant Data Highlighted in The BIO

November 25, 2025

Tags : Press highlights ,

Qureator Launches First Anti–PD-1/L1 Combination and PD-1/VEGF Bispecific Campaigns with Special Launch Offer !!!

November 7, 2025

Tags : Spotlight ,

Qureator Showcases Next-Generation Immuno-Oncology Platform at SITC 2025

October 28, 2025

Tags : Activities ,

Qureator Achieves World’s First FDA IND Approval Using Only Human Vascularized Organoid Efficacy Data

October 27, 2025

Tags : Press highlights , Spotlight ,

Qureator Unveils AI-Driven Lab-in-the-Loop Platform for Scalable, Personalized Drug Discovery at BIO 2025

June 15, 2025

Tags : Activities ,

Qureator Showcases Groundbreaking 3D Blood-Retinal Barrier Model at ARVO 2025

May 3, 2025

Tags : Activities ,

Qureator to Showcase Breakthrough Vascularized 3D Tumor Models at AACR 2025

April 27, 2025

Tags : Activities ,

Paul Park Joins Qureator as Chief Business Officer

Qureator and Physicians Committee for Responsible Medicine Announce Joint Workshop at SOT 2026

Qureator’s Historic FDA IND Approval Based on Human-Relevant Data Highlighted in The BIO

Qureator Launches First Anti–PD-1/L1 Combination and PD-1/VEGF Bispecific Campaigns with Special Launch Offer !!!

Qureator Showcases Next-Generation Immuno-Oncology Platform at SITC 2025

Qureator Achieves World’s First FDA IND Approval Using Only Human Vascularized Organoid Efficacy Data

Qureator Unveils AI-Driven Lab-in-the-Loop Platform for Scalable, Personalized Drug Discovery at BIO 2025

Qureator Showcases Groundbreaking 3D Blood-Retinal Barrier Model at ARVO 2025

Qureator to Showcase Breakthrough Vascularized 3D Tumor Models at AACR 2025

Let’s Collaborate

Test your treatment with human tissue before putting it into human bodies.